Innate Pharma schedules Q3 update for November 5, 2026

The webcast replay will be available on Innate Pharma’s website for 90 days following the November 5 event.

Rhea-AI Filing Summary

Innate Pharma SA will hold a conference call on November 5, 2026, at 2:00 p.m. CET / 8:00 a.m. ET for a business and financial update for the third quarter of 2026. Participants include Chief Executive Officer Jonathan Dickinson, Chief Medical Officer Markus Jensen, Chief Operating Officer Yannis Morel, Stéphanie Cornen, Vice President of Investor Relations and Communications, and Frédéric Lombard, Senior Vice President and Chief Financial Officer. A webcast replay will be available on the company’s website for 90 days following the event.

Key Figures

Conference call date: November 5, 2026 Conference call time: 2:00 p.m. CET / 8:00 a.m. ET Webcast replay availability: 90 days

3 metrics

Conference call date November 5, 2026 Business and financial update for the third quarter of 2026

Conference call time 2:00 p.m. CET / 8:00 a.m. ET November 5, 2026

Webcast replay availability 90 days Following the event

Key Terms

clinical-stage, antibody-drug conjugates (ADCs), Nectin-4 ADC, T-cell lymphomas

4 terms

clinical-stage medical

"global, clinical-stage biotechnology company"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

antibody-drug conjugates (ADCs) medical

"pipeline is centered on antibody-drug conjugates (ADCs)"

Antibody-drug conjugates (ADCs) are advanced medicines that combine a targeted antibody with a powerful drug, acting like a guided missile to deliver treatment directly to cancer cells while sparing healthy tissue. This precision approach can improve effectiveness and reduce side effects, making ADCs a promising area of biotech innovation. For investors, advancements in ADC technology can signal potential growth opportunities in the pharmaceutical and healthcare sectors.

Nectin-4 ADC medical

"a differentiated Nectin-4 ADC in clinical development"

T-cell lymphomas medical

"lacutamab, developed with Sobi for T-cell lymphomas"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/20/2026 - 06:09 AM EDT Accepted by SEC EDGAR 10/20/2026 - 06:09 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Tuesday October 20, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated October 20, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: October 20, 2026 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson

Title:    Chief Executive officer

EXHIBIT 99.1

INNATE PHARMA ANNOUNCES CONFERENCE CALL FOR THIRD QUARTER 2026 BUSINESS AND FINANCIAL UPDATE

Marseille, France, October 20, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026.

Participants during the call will be:

•Jonathan Dickinson, Chief Executive Officer

•Markus Jensen, Vice President, Chief Medical Officer

•Yannis Morel, Executive Vice President, Chief Operating Officer

•Stéphanie Cornen, Vice President, Investor Relations and Communications

•Frédéric Lombard, Senior Vice President, Chief Financial Officer

Event details

Date and time: November 5, 2026 at 2:00 p.m. CET / 8:00 a.m. ET

Webcast link: Click here

Conference call link: Click here

This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code: FR0010331421

Ticker code: Euronext Paris: IPH | Nasdaq: IPHA

LEI: 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen

VP, Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations 

investors@innate-pharma.fr

Media 

communication@innate-pharma.fr 

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 13.0 KB